Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Hum Mutat ; 25(3): 325, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15712364

RESUMEN

Crigler-Najjar syndrome types I and II (CN1 and CN2) are usually inherited as autosomal recessive conditions and are characterized by non-hemolytic unconjugated hyperbilirubinaemia. CN1 is the most severe form, associated with the absence of hepatic bilirubin-uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1) activity. CN2 presents intermediate levels of hyperbilirubinaemia as a result of an incomplete deficiency of hepatic UGT1A1 activity. Here, we present the analysis of UGT1A1 gene in 31 unrelated Crigler-Najjar (CN) syndrome patients. This analysis allowed us to identify 22 mutations, 12 of which were not previously described, expanding the spectrum of known UGT1 mutations to 77. Novel mutations, considered pathogenic, including one nonsense mutation, two altered splice sites, one single base deletion and nine missense mutations were identified in coding exons of the UGT1A1gene and flanking introns. Several novel missense mutations localize in critical domain of UGT1A1 enzyme. In addition, the evaluation of Gilbert-type promoter of UGT1A1in Crigler-Najjar (CN) syndrome patients was performed. The polymorphisms of the promoter region can modify the UGT1A1 mutation phenotype. This study represents the molecular characterization of the largest cohort of Italian Crigler-Najjar Gilbert syndrome patients studied so far; increase the mutational spectrum of UGT1A1 allelic variants worldwide and provide a new insight useful for clinical diagnosis and genetic counseling.


Asunto(s)
Codón sin Sentido , Síndrome de Crigler-Najjar/genética , Glucuronosiltransferasa/genética , Mutación Missense , Mutación Puntual , Sitios de Empalme de ARN/genética , Eliminación de Secuencia , Alelos , Sustitución de Aminoácidos , Bilirrubina/sangre , Estudios de Cohortes , Consanguinidad , Síndrome de Crigler-Najjar/clasificación , Croacia/etnología , Exones/genética , Femenino , Genotipo , Glucuronosiltransferasa/química , Glucuronosiltransferasa/deficiencia , Humanos , Intrones/genética , Italia , Masculino , Marruecos/etnología , Fenotipo , Polimorfismo Genético , Regiones Promotoras Genéticas/genética , Población Blanca/genética
2.
Haematologica ; 89(9): 1046-53, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15377465

RESUMEN

BACKGROUND AND OBJECTIVES: Interferon alpha2a (IFNalpha2a) mediates important antiviral, antiproliferative and immunomodulatory responses and is employed in the treatment of human diseases, including chronic myelogenous leukemia. Here, we report the IFNalpha2a-dependent expression profiles of three malignant cell lines derived from liver, lymphocytes and muscle. DESIGN AND METHODS: The experiments were performed in the presence of cycloheximide, thus our results exclusively reflect direct transcriptional modulation. The short exposure time i.e. 5 hours evidences only the early events, excluding the effects of complex phenotypic changes on the expression. RESULTS: Our findings indicate that IFNalpha2a rapidly up-regulates the expression of STAT1, STAT2 and ISGF3G genes. This activity should result in the amplification of the cellular response to the cytokine. Moreover, IFNalpha2a directly modulates the expression of: (i) important transcriptional factors, e.g. IRF1 and IRF7 which control pivotal cellular events, and (ii) enzymes involved in the IFNalpha2a-dependent antiviral and apoptotic response. Interestingly, we showed that the cytokine induces transcriptional expression of Sjögren's syndrome antigen A1, a protein involved in several autoimmune diseases. INTERPRETATION AND CONCLUSIONS: The observed changes induced by IFNalpha2a could be related to the development of autoimmune syndromes observed during IFNalpha2a treatment. A number of genes transcriptionally regulated by the cytokine have been identified for the first time; these might represent additional effectors of IFNalpha2a activity.


Asunto(s)
Citocinas/genética , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Interferón-alfa/farmacología , Proteínas de Neoplasias/genética , Transcripción Genética/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/biosíntesis , Proteínas Reguladoras de la Apoptosis/genética , Secuencia de Bases , Carcinoma Hepatocelular/patología , Línea Celular Tumoral/efectos de los fármacos , Línea Celular Tumoral/metabolismo , Cicloheximida/farmacología , Citocinas/biosíntesis , Humanos , Interferón alfa-2 , Subunidad gamma del Factor 3 de Genes Estimulados por el Interferón/biosíntesis , Subunidad gamma del Factor 3 de Genes Estimulados por el Interferón/genética , Células K562/efectos de los fármacos , Células K562/metabolismo , Neoplasias Hepáticas/patología , Proteínas de Transporte de Membrana/biosíntesis , Proteínas de Transporte de Membrana/genética , Datos de Secuencia Molecular , Proteínas de la Mielina/biosíntesis , Proteínas de la Mielina/genética , Proteínas Proteolipídicas Asociadas a Mielina y Linfocito , Proteínas de Neoplasias/biosíntesis , Análisis de Secuencia por Matrices de Oligonucleótidos , Regiones Promotoras Genéticas , Inhibidores de la Síntesis de la Proteína/farmacología , Proteolípidos/biosíntesis , Proteolípidos/genética , Proteínas Recombinantes , Rabdomiosarcoma/patología , Ribonucleoproteínas/biosíntesis , Ribonucleoproteínas/genética , Factor de Transcripción STAT1/biosíntesis , Factor de Transcripción STAT1/genética , Factor de Transcripción STAT2/biosíntesis , Factor de Transcripción STAT2/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...